Literature DB >> 9950368

Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions.

M G Hamshere1, H Harley, P Harper, J D Brook, J F Brookfield.   

Abstract

Myotonic dystrophy (DM) was the first of a group of diseases to be identified for which the genetic basis is the expansion of a triplet repeat. Myotonic dystrophy also exhibits anticipation, in which the disease worsens through successive generations. These two features have led many groups to analyse whether a significant negative correlation between triplet repeat length and severity of disease exists. However, the recent molecular finding that two distinct subsets of classically affected DM patients exist, those who export expansion derived DMPK RNA and those who do not, led us to question whether combining data from these two sets of patients is statistically valid. We found that although patients with small expansions showed a significant correlation between age at onset and triplet repeat length, those with larger expansions did not. The theoretical triplet repeat size, which separated the two groups, was also deduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950368      PMCID: PMC1762955     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

1.  Congenital myotonic dystrophy.

Authors:  S Gulati; M Kabra; S Gera; V Kalra; R Saxena; I C Verma
Journal:  Indian J Pediatr       Date:  2001-05       Impact factor: 1.967

2.  Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions.

Authors:  Jovan Pešović; S Perić; M Brkušanin; G Brajušković; V Rakočević-Stojanović; Dušanka Savić-Pavićević
Journal:  Neurogenetics       Date:  2017-09-23       Impact factor: 2.660

3.  MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1.

Authors:  Vincent Huin; Francis Vasseur; Susanna Schraen-Maschke; Claire-Marie Dhaenens; Patrick Devos; Kathy Dupont; Nicolas Sergeant; Luc Buée; Arnaud Lacour; Hélène Hofmann-Radvanyi; Bernard Sablonnière
Journal:  J Neurol       Date:  2012-11-16       Impact factor: 4.849

Review 4.  Genetics and molecular pathogenesis of the myotonic dystrophies.

Authors:  John W Day; Laura P W Ranum
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

5.  Improved method for molecular diagnosis of myotonic dystrophy type 1 (DM1).

Authors:  Nihan Erginel-Unaltuna; Fahri Akbas
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 6.  Myotonic dystrophy: RNA pathogenesis comes into focus.

Authors:  Laura P W Ranum; John W Day
Journal:  Am J Hum Genet       Date:  2004-04-02       Impact factor: 11.025

7.  Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.

Authors:  Erik-Jan Kamsteeg; Wolfram Kress; Claudio Catalli; Jens M Hertz; Martina Witsch-Baumgartner; Michael F Buckley; Baziel G M van Engelen; Marianne Schwartz; Hans Scheffer
Journal:  Eur J Hum Genet       Date:  2012-05-30       Impact factor: 4.246

Review 8.  Molecular genetics and genetic testing in myotonic dystrophy type 1.

Authors:  Dušanka Savić Pavićević; Jelena Miladinović; Miloš Brkušanin; Saša Šviković; Svetlana Djurica; Goran Brajušković; Stanka Romac
Journal:  Biomed Res Int       Date:  2013-03-18       Impact factor: 3.411

9.  Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress.

Authors:  Andrie Koutsoulidou; Tassos C Kyriakides; George K Papadimas; Yiolanda Christou; Evangelia Kararizou; Eleni Zamba Papanicolaou; Leonidas A Phylactou
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.

Authors:  Adrian J Waite; Dirk Bäumer; Simon East; James Neal; Huw R Morris; Olaf Ansorge; Derek J Blake
Journal:  Neurobiol Aging       Date:  2014-01-17       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.